1471-2407-6-67 1471-2407 Research article <p>Polymorphisms of the <it>XRCC1</it>, <it>XRCC3 </it>and <it>XPD </it>genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study</p> Skjelbred Furu Camilla camilla-furu.skjelbred@sthf.no Sæbø Mona mona.sabo@hit.no Wallin Håkan hwa@ami.dk Nexø Andersen Bjørn nexo@humgen.au Hagen Christian Per per.chr.hagen@hit.no Lothe Marie Bowitz Inger ingermariebowitzlothe@ulleval.no Aase Steinar steinar.aase@helse-bergen.no Johnson Egil egil.johnson@ulleval.no Hansteen Inger-Lise inger-lise.hansteen@sthf.no Vogel Ulla ubv@ami.dk Kure H Elin elin.kure@hit.no

Department of Laboratory Medicine, Section of Medical Genetics, Telemark Hospital, N-3710 Skien, Norway

Telemark University College, Faculty of Arts and Sciences, Department of Environmental and Health Studies, Hallvard Eikas plass, N-3800 Bø i Telemark, Norway

National Institute of Occupational Health, Copenhagen, Denmark

Institute of Human Genetics, University of Aarhus, Aarhus, Denmark

Department of Pathology, Ullevaal University Hospital, Oslo, Norway

Department of Pathology, The Gade Institute, Haukeland University Hospital / University of Bergen, N-5021 Bergen, Norway

Department of Gastroenterological Surgery, Ullevaal University Hospital, Oslo, Norway

BMC Cancer 1471-2407 2006 6 1 67 http://www.biomedcentral.com/1471-2407/6/67 16542436 10.1186/1471-2407-6-67
23 11 2005 16 3 2006 16 3 2006 2006 Skjelbred et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Genetic polymorphisms in DNA repair genes may influence individual variation in DNA repair capacity, which may be associated with risk of developing cancer. For colorectal cancer the importance of mutations in mismatch repair genes has been extensively documented. Less is known about other DNA repair pathways in colorectal carcinogenesis. In this study we have focused on the XRCC1, XRCC3 and XPD genes, involved in base excision repair, homologous recombinational repair and nucleotide excision repair, respectively.

Methods

We used a case-control study design (157 carcinomas, 983 adenomas and 399 controls) to test the association between five polymorphisms in these DNA repair genes (XRCC1 Arg194Trp, Arg280His, Arg399Gln, XRCC3 Thr241Met and XPD Lys751Gln), and risk of colorectal adenomas and carcinomas in a Norwegian cohort. Odds ratio (OR) and 95% confidence interval (95% CI) were estimated by binary logistic regression model adjusting for age, gender, cigarette smoking and alcohol consumption.

Results

The XRCC1 280His allele was associated with an increased risk of adenomas (OR 2.30, 95% CI 1.19–4.46). The XRCC1 399Gln allele was associated with a reduction of risk of high-risk adenomas (OR 0.62, 95% CI 0.41–0.96). Carriers of the variant XPD 751Gln allele had an increased risk of low-risk adenomas (OR 1.40, 95% CI 1.03–1.89), while no association was found with risk of carcinomas.

Conclusion

Our results suggest an increased risk for advanced colorectal neoplasia in individuals with the XRCC1 Arg280His polymorphism and a reduced risk associated with the XRCC1 Arg399Gln polymorphism. Interestingly, individuals with the XPD Lys751Gln polymorphism had an increased risk of low-risk adenomas. This may suggest a role in regression of adenomas.

Background

In Western populations the vast majorities of colorectal cancers (CRC) arise from benign adenomatous polyps (colorectal adenomas) and evolve through the adenoma-carcinoma sequence, a multistep process of genetic alterations 12. The lifetime risk of CRC in a normal population is low in comparison to the prevalence of adenomas. This indicates that only a few of the adenomas will develop into a carcinoma. However, from the perspective of understanding the genetic events involved in colonic neoplasia, these early lesions are valuable endpoints.

The risk of sporadic CRC is associated with lifestyle factors like cigarette smoking and alcohol consumption which may be modulated by several genetic factors of low penetrance 34. Cigarette smoke and alcohol may act as sources of chemical carcinogens (including nitrosamines, heterocyclic amines and polycyclic hydrocarbons), reactive oxygen species (ROS) 56 and DNA adduct formation 3. Genetic polymorphisms in DNA repair genes may influence individual variation in DNA repair capacity, which may be associated with risk of developing cancer 7. During the past years, an increasing number of DNA repair gene polymorphisms have been described and their involvement in carcinogenesis investigated. For colorectal cancer, the importance of mutations in mismatch repair (MMR) genes has been extensively documented. Less is known about other DNA repair pathways in colorectal carcinogenesis, and in this study we have focused on the XRCC1, XRCC3 and XPD genes.

The DNA repair gene XRCC1 gene codes for a protein involved in the repair of single-strand breaks (SSB) and in base excision repair (BER) of damaged bases caused by endogenous and exogenous oxidants. Three polymorphisms occurring at conserved sequences in the XRCC1 gene were reported by Shen et al. 8. These coding polymorphisms, resulting in amino acid substitutions, were detected at codons 194 (Arg-Trp), 280 (Arg-His) and 399 (Arg-Gln). Most studies report a reduced risk of cancer associated with the 194Trp allele 9. The 399 polymorphism have been associated with a number of cancers, although results have been inconsistent 9101112131415. Few studies have investigated the association between the XRCC1 280His allele and risk of cancer. No association has been observed with colorectal cancer 13, but an increased risk has been reported with lung cancer 16 and breast cancer 17.

The XRCC3 gene codes for a protein involved in homologous recombinational repair (HRR) of double-strand DNA and is required for genomic stability 1819. The XRCC3 gene has a sequence variation in exon 7 (C18067T), which results in an amino acid substitution at codon 241 (Thr241Met) that may affect the enzyme's function and/or its interaction with other proteins involved in DNA damage and repair 20. Molecular epidemiological studies have linked this XRCC3 polymorphism to increased risk of breast cancer 21, lung cancer 22, skin cancer 23 and colorectal cancer 14. The results have been inconsistent 24.

The XPD protein is involved in the nucleotide excision repair (NER) pathway 25, which recognizes and repairs a wide range of structurally unrelated lesions such as bulky adducts and thymidine dimers 262728. The XPD gene encodes a helicase that is a component of the transcription factor TFIIH 29. Mutations in the XPD gene can diminish the activity of TFIIH complexes increasing the likelihood of repair defects, transcription defects, and abnormal responses to apoptosis 30. The XPD Lys751Gln substitution is attributed to a (A→C) transversion at exon 23 8. Several epidemiological studies have investigated the association between XPD polymorphisms and cancer. Smoking related cancers and skin cancers are most frequently investigated, but it is not yet established whether the polymorphism is linked to risk of lung cancer 3132. No association has been observed with the various stages of the adenoma-carcinoma sequence or with colorectal cancer 1415.

In the present study we used a case-control design to test the association between five amino acid substitution variants of DNA repair genes, XRCC1 (Arg194Trp), XRCC1 (Arg280His), XRCC1 (Arg399Gln), XRCC3 (Thr241Met) and XPD (Lys751Gln), and colorectal adenoma/cancer risk in a Norwegian cohort. The main focus was to investigate if these polymorphisms are linked to risk of colorectal adenoma and carcinoma. By studying repair genes in the various stages of the adenoma-carcinoma sequence we may gain new information on the significance of polymorphisms in neoplastic tissues during transition.

Methods

The cohort in the KAM (Kolorektal cancer, Arv og Miljø) molecular epidemiological study is based on the screening group of the Norwegian Colorectal Cancer Prevention study (The NORCCAP study) in the county of Telemark 33. The ID number for the NORCCAP study at ClinicalTrials.gov is NCT00119912 34. In addition, patients diagnosed with colorectal cancer, operated on at Telemark Hospital (Skien) and Ulleval University Hospital (Oslo) were included. The KAM cohort is based on an ethnic homogeneous group of Norwegian origin.

The KAM biobank consists of blood and tissue samples from 1044 individuals identified with adenomas in the large intestine (991 high- and low-risk adenomas, 53 hyperplastic polyps), 160 with colorectal cancer and 400 controls, defined as individuals with normal findings at flexible sigmoidoscopy screening. All of the participants completed a questionnaire on demographics, health status, dietary; and smoking habits, alcohol consumption, physical exercise and occupation. The questionnaire contained information on a family history of adenomas and carcinomas, and the included cases and controls had no known personal history of genetic predisposition. The KAM study is approved by the Regional Ethics Committee and the Data Inspectorate.

In the present study we analyzed available blood samples from 157 cases with carcinoma, 983 cases with adenomas, (i.e. 227 high-risk and 756 low-risk adenomas) and 399 controls. A high-risk adenoma is defined as an adenoma measuring ≥ 10 mm in diameter and/or with villous components and/or showing severe dysplasia 33.

The distribution of age, gender, cigarette smoking and alcohol consumption among controls and cases with colonic carcinomas and adenomas are shown in Table 1.

<p>Table 1</p>

Distributions of age, gender, cigarette smoking and alcohol consumption among controls and cases with colorectal carcinomas and adenomas.

Controls

Carcinomas

Adenomas, all

High-risk adenomas

Low-risk adenomas


No (%)

No (%)

No (%)

No (%)

No (%)

No. of subjects

399

157

983

227

756

Gendera

Male

157 (39.3)

87 (55.4)

603 (61.3)

150 (66.1)

453 (59.9)

Female

242 (60.7)

70 (44.6)

380 (38.7)

77 (33.9)

303 (40.1)

Ageb

Mean (SD)

54.2 (3.3)

67.9 (11.2)

57.3 (3.7)

57.3 (3.5)

57.3 (3.8)

Smoking status *

Never smoked

155 (46.7)

33(31.1)

253 (30.6)

51 (27.0)

202 (31.7)

Ever smoked

177 (53.3)

73 (68.9)

574 (69.4)

138 (73.0)

436 (68.3)

Mean no. of cigarette years (SD)

249(229)

383(339)

360(263)

389(244)

351(269)

Alcohol consumption *

< 1 unit/month

72 (21.7)

36 (34.0)

180 (21.8)

43 (22.8)

137 (21.5)

≥ 1 unit/month

260 (78.3)

70 (66.0)

647 (78.2)

146 (77.2)

501 (78.5)

Mean units of alcohol per month (SD)

11.1 (12.2)

15.5 (22.3)

16.4 (22.9)

18.4 (29.8)

15.8 (20.4)

* Missing values for cigarette smoking and alcohol consumption gave rise to diminished number of cases and controls.

a There are significant differences in the number of males and females in the control group and the case groups, p < 10-4 (test for comparison of two proportions).

b There are significant differences in age among the control group and the case groups, p < 10-4 (Mann-Whitney test).

Genomic DNA was isolated from blood samples according to standard procedures 35 with minor modifications. In brief, whole blood samples (anticoagulated) was mixed with a threefold volume of lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 1 mM EDTA pH 7.4) and incubated at 4°C for at least 30 min. The lysate was then centrifuged, and pellet of intact leukocytes was resuspended in 10 ml SE buffer (75 mM NaCl, 24 mM EDTA pH 8.0) 500 μl SDS (20 %) and 50 μl Proteinase K (20 mg/ml) and incubated overnight at 40°C. After digestion, 3.5 ml 6 M NaCl was added to the lysate and the mixture was shaken vigorously and then centrifuged to pellet the cellular proteins. DNA in the supernatant was then precipitated with 2 volumes of absolute ethanol, washed in 70 % ethanol and resuspended in TE buffer (10 mM TrisHCl, 0.1 mM EDTA, pH 7.5).

Genotype analysis of the five single nucleotide polymorphisms (SNPs) of the DNA repair genes XRCC1, XRCC3 and XPD was carried out using the TaqMan allelic discrimination assay on a Sequence Detection System ABI 7000 (Applied Biosystems). The XRCC1 polymorphisms (XRCC1 Arg194Trp (rs#1799782), XRCC1 Arg280His (rs#25489), XRCC1 Arg399Gln (rs#25487)) were determined in 12 μl reactions containing 1× MasterMix, 200 nM of each probe, 900 nM primers, and 50–100 ng of genomic DNA. Cycling conditions were as follows: 50°C for 2 min, 95°C for 10 min, and 45 cycles of 95°C for 15 s and 60°C for 1 min. Primers and probes are described in Table 2. The XRCC3 Thr241Met (rs#861539) and XPD Lys751Gln (rs#1052559) were genotyped as described previously 2436. Controls were included in each run and repeated genotyping of a random 10 % subset yielded 100 % identical genotypes.

<p>Table 2</p>

Design of primers and TaqMan probes for allelic discrimination assay.

Primer /Probe

Sequence


XRCC1 codon 194

Forward primer:

5'-GAG GAT GAG AGC GCC AAC TC-3'

Reverse primer:

5'-TCA CTC AGG ACC CAC GTT GTC-3'

Probe C allele:

5'-VIC-TCT TCA GC

    C
GGA TCA-MGB/NFQ-3'

Probe T allele:

5'-FAM-TCT TCA GC

    T
GGA TCA A-MGB/NFQ-3'

XRCC1 codon 280

Forward primer:

5'-GGT GCT AAC CTA ATC TAC TCT TTG TCT TC-3'

Reverse primer:

5'-TGG GCT CGG TGC CTT CT-3'

Probe G allele:

5'-VIC-AGC TCC AAC TC

    G
TAC C-MGB/NFQ-3'

Probe A allele:

5'-FAM-AGC TCC AAC TC

    A
TAC C-MGB/NFQ-3'

XRCC1 codon 399

Forward primer:

5'-GAG TGG GTG CTG GAC TGT CA-3'

Reverse primer:

5'-CAT TGC CCA GCA CAG GAT AA-3'

Probe G allele:

5'-VIC-CCT CCC

    G
GA GGT AA-MGB/NFQ-3'

Probe A allele:

5'-FAM-CCT CCC

    A
GA GGT AAG-MGB/NFQ-3'

The bold underlined letters represent the polymorphic positions.

SPSS (Statistical Packages for the Social Sciences) 12.0.1 for Windows was used for the statistic calculations. Odds ratios (OR) and 95 % confidence intervals (CI) were calculated using binary logistic regression to assess the relationship between each polymorphism and the colorectal adenoma or carcinoma cases. Two separate ORs were calculated, one adjusted for age only (Table 3), and the other for age, gender, cigarette smoking (number of cigarette years) and alcohol consumption (units of alcohol per month) (Table 4). Due to missing data on cigarette smoking and alcohol consumption (67 controls, 51 carcinomas and 156 adenomas) the number of case and controls used to calculate OR adjusted for age, gender, cigarette smoking and alcohol consumption (in Table 4) is reduced. Possible combined effects of the XRCC1 Arg280His and XRCC1 Arg399Gln polymorphisms were investigated in a two by three table (Table 5).

<p>Table 3</p>

Distributions of XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XRCC3 Thr241Met and XPD Lys751Gln genotypes and development of colorectal carcinomas and adenomas. ORs are adjusted for age.

Genotypes

Controls

Carcinomas

OR (95% CI)

Adenomas

OR (95% CI)

High-risk adenomas

OR (95% CI)

Low-risk adenomas

OR (95% CI)


XRCC1 Arg194Trp

Arg/Arg (CC)

352

135

1a

864

1a

197

1a

667

1a

Arg/Trp (CT)

46

19

0.99 (0.42–2.33)

115

1.07 (0.72–1.58)

29

1.35 (0.78–2.32)

86

0.99 (0.66–1.50)

Trp/Trp (TT)

1

2

-

4

-

1

-

3

-

Arg/Trp + Trp/Trp

47

21

1.00 (0.43–2.32)

119

1.09 (0.74–1.60)

30

1.38 (0.81–2.36)

89

1.01 (0.68–1.52)

Missing

1

XRCC1Arg280His

Arg/Arg (GG)

381

145

1a

906

1a

207

1a

699

1a

Arg/His (GA)

18

12

1.72 (0.58–5.04)

77

1.68 (0.96–2.93)

20

2.25 (1.10–4.60)

57

1.55 (0.87–2.76)

His/His (AA)

0

0

-

0

-

0

-

0

-

XRCC1Arg399Gln

Arg/Arg (GG)

148

63

1a

391

1a

100

1a

291

1a

Arg/Gln (GA)

187

70

0.74 (0.41–1.33)

443

0.82 (0.62–1.08)

95

0.67 (0.46–0.99)

348

0.87 (0.65–1.16)

Gln/Gln (AA)

64

24

0.91 (0.42–1.98)

149

0.88 (0.61–1.29)

32

0.65 (0.38–1.13)

117

0.96 (0.65–1.42)

Arg/Gln + Gln/Gln

251

94

0.78 (0.45–1.35)

592

0.84 (0.64–1.08)

127

0.67 (0.46–0.96)

465

0.90 (0.68–1.17)

XRCC3 Thr241Met

Thr/Thr (CC)

138

64

1a

380

1a

88

1a

292

1a

Thr/Met (CT)

201

73

1.15 (0.64–2.08)

456

0.83 (0.63–1.10)

109

0.86 (0.58–1.27)

347

0.81 (0.61–1.09)

Met/Met (TT)

60

20

1.09 (0.46–2.55)

147

0.92 (0.63–1.35)

30

0.84 (0.48–1.47)

117

0.97 (0.65–1.45)

Thr/Met + Met/Met

261

93

1.14 (0.64–2.01)

603

1.11 (0.23–0.85)

139

0.86 (0.59–1.24)

464

0.85 (0.65–1.12)

XPD Lys751Gln

Lys/Lys (AA)

175

58

1a

364

1a

87

1a

277

1a

Lys/Gln (AC)

173

76

0.92 (0.52–1.63)

463

1.36 (1.03–1.78)

100

1.11 (0.75–1.63)

363

1.43 (1.07–1.89)

Gln/Gln (CC)

50

22

0.84 (0.36–1.95)

155

1.55 (1.05–2.30)

40

1.38 (0.80–2.37)

115

1.56 (1.03–2.36)

Lys/Gln + Gln/Gln

223

98

0.90 (0.52–1.54)

618

1.40 (1.08–1.81)

140

1.17 (0.81–1.68)

478

1.46 (1.11–1.90)

Missing

1

1

1

1

a The genotype served as reference category

<p>Table 4</p>

Distributions of XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XRCC3 Thr241Met and XPD Lys751Gln genotypes and development of colorectal carcinomas and adenomas. ORs are adjusted for age, gender, cigarette smoking and alcohol consumption.

Genotypes

Controls

Carcinomas

OR (95% CI)

Adenomas

OR (95% CI)

High-risk adenomas

OR (95% CI)

Low-risk adenomas

OR (95% CI)


XRCC1 Arg194Trp

Arg/Arg (CC)

292

92

1a

734

1a

166

1a

568

1a

Arg/Trp (CT)

39

11

0.82 (0.27–2.47)

89

0.95 (0.61–1.48)

22

1.37 (0.72–2.60)

67

0.85 (0.53–1.36)

Trp/Trp (TT)

1

2

-

4

-

1

-

3

-

Arg/Trp + Trp/Trp

40

13

0.84 (0.28–2.48)

93

0.96 (0.62–1.49)

23

1.35 (0.71–2.56)

70

0.87 (0.55–1.38)

Missing

1

XRCC1Arg280His

Arg/Arg (GG)

319

100

1a

764

1a

174

1a

590

1a

Arg/His (GA)

13

6

1.48 (0.29–7.48)

63

2.30 (1.19–4.46)

15

3.82 (1.59–9.18)

48

2.07 (1.05–4.10)

His/His (AA)

0

0

-

0

-

0

-

0

-

XRCC1Arg399Gln

Arg/Arg (GG)

119

39

1a

326

1a

82

1a

244

1a

Arg/Gln (GA)

159

51

0.87 (0.43–1.78)

371

0.74 (0.54–1.01)

79

0.59 (0.37–0.94)

292

0.79 (0.57–1.09)

Gln/Gln (AA)

54

16

1.05 (0.40–2.75)

130

0.93 (0.61–1.42)

28

0.73 (0.39–1.37)

102

0.97 (0.62–1.51)

Arg/Gln + Gln/Gln

213

67

0.91 (0.47–1.79)

500

0.78 (0.59–1.05)

107

0.62 (0.41–0.96)

394

0.83 (0.61–1.13)

XRCC3 Thr241Met

Thr/Thr (CC)

116

45

1a

324

1a

70

1a

254

1a

Thr/Met (CT)

169

48

1.18 (0.57–2.42)

380

0.83 (0.61–1.14)

91

1.06 (0.67–1.68)

289

0.78 (0.57–1.08)

Met/Met (TT)

47

13

1.29 (0.45–3.69)

123

1.03 (0.66–1.60)

28

1.25 (0.65–2.39)

95

1.01 (0.64–1.59)

Thr/Met + Met/Met

216

61

1.20 (0.60–2.39)

502

0.88 (0.65–1.18)

119

1.10 (0.71–1.71)

384

0.83 (0.61–1.13)

XPD Lys751Gln

Lys/Lys (AA)

148

43

1a

300

1a

69

1a

231

1a

Lys/Gln (AC)

142

47

0.81 (0.40–1.67)

390

1.35 (0.99–1.83)

86

1.27 (0.81–2.01)

304

1.33 (0.97–1.84)

Gln/Gln (CC)

41

15

1.00 (0.38–2.62)

136

1.66 (1.07–2.58)

34

1.59 (0.85–2.99)

102

1.61 (1.02–2.54)

Lys/Gln + Gln/Gln

183

62

0.86 (0.44–1.68)

526

1.42 (1.06–1.89)

120

1.35 (0.88–2.06)

406

1.40 (1.03–1.89)

Missing

1

1

1

a The genotype served as reference category

<p>Table 5</p>

Combinations of XRCC1 Arg280His and XRCC1 Arg399Gln polymorphisms and risk of colorectal carcinomas and adenomas. ORs are adjusted for age.

Case group

OR (95 % CI) (N case/N controls)


XRCC1 Arg399Gln

XRCC1 Arg280His

Carcinomas

GG

GA

GG

1.0a (56/137)

1.93 (0.44–8.49) (7/11)

GA

0.76 (0.41–1.38) (65/180)

1.18 (0.20–7.02) (5/7)

AA

0.96 (0.44–2.09) (24/64)

-

Adenomas

GG

GA

GG

1.0a (341/137)

1.75 (0.85–3.63) (50/11)

GA

0.85 (0.64–1.13) (415/180)

1.22 (0.50–3.00) (27/7)

AA

0.93 (0.44–1.36) (149/64)

-

High-risk adenomas

GG

GA

GG

1.0a (83/137)

2.92 (1.20–7.10) (17/11)

GA

0.77 (0.51–1.15) (92/180)

0.63 (0.14–2.71) (3/7)

AA

0.74 (0.42–1.29) (32/64)

-

Low-risk adenomas

GG

GA

GG

1.0a (258/137)

1.43 (0.66–3.09) (33/11)

GA

0.88 (0.65–1.18) (324/180)

1.47 (0.59–3.66) (24/7)

AA

1.00 (0.67–1.48) (117/64)

a The genotype served as a reference category

Given the allele frequency of polymorphism of the controls and assuming Hardy-Weinberg equilibrium, we had a 65 % chance (at the 5 % level) of detecting an OR of 2.25 for XRCC1 codon 280 heterozygotes among high-risk adenomas and 81 % among low-risk adenomas. We had 60 % chance of detecting an OR of 0.65 among carriers of the variant allele of XRCC1 codon 399 among high-risk adenomas and 81 % among low-risk adenomas. For the XPD codon 751 polymorphism, we had 54 % chance of detecting an OR of 1.36 and 1.55 among heterozygote and homozygote carriers among high-risk adenomas and 79 % power among low-risk adenomas.

Haplotypes were estimated and ORs calculated using the Hplus program available online 37. Hplus is a SNP analysis tool for performing haplotype estimation according to the distribution of genotypes in a population. Such haplotype-based methods should be used either for multiple SNPs within candidate genes or when selected SNPs are physically closed to each other 38. We used this method to estimate haplotypes of three SNPs within the XRCC1 gene.

Results

The genotypic distributions of the five polymorphisms in the three DNA repair genes for both cases and controls are shown in Table 3. The frequencies for the XRCC1 194Trp allele, XRCC1 280His allele, XRCC1 399Gln allele, XRCC3 241Met allele and XPD 751Gln allele among the controls were respectively, 0.06, 0.02, 0.39, 0.40 and 0.34. The genotype distributions were all in Hardy-Weinberg equilibrium and the distributions of the alleles in the control group are in agreement with those found in other Caucasian populations 9, and in other Scandinavian populations for the XRCC3 241Met allele and XPD 751Gln allele 2436. Tables 3 and 4 also presents the estimates of ORs of colorectal adenomas and carcinomas associated with the various XRCC1, XRCC3 and XPD polymorphisms.

The XRCC1 280His allele was associated with an increased risk of adenomas with OR of 2.30 (95% CI 1.19–4.46) (OR 3.82, 95% CI 1.59–9.18 and OR 2.07, 95 % CI 1.05–4.10 for high- and low-risk adenomas, respectively). Among the carcinoma cases the same trend was observed although not significant. The XRCC1 399Gln allele showed a trend towards risk reduction for carcinomas and adenomas, reaching statistical significance only for the high-risk adenomas, OR of 0.62 (95% CI 0.41–0.96). There was no significant association between XRCC1 194Trp allele and risk of colorectal adenomas and carcinomas. The combination of the XRCC1 codon 280 and XRCC1 codon 399 polymorphisms showed a significant positive association for carriers of the XRCC1 codon 280 variant allele and XRCC1 codon 399 wild type allele, in the high-risk adenomas only, OR of 2.92 (95 % CI 1.20–7.10).

No significant association was found between the XRCC3 Thr241Met polymorphism and risk of colorectal adenomas and carcinomas.

Further, no significant association was found between the XPD Lys751Gln polymorphism and colorectal cancer. There was, however, a significant association between the XPD 751Gln allele and risk of adenomas with OR of 1.42 (95% CI 1.06–1.89). This association was limited to the low-risk adenoma group OR of 1.40 (95% CI 1.03–1.89).

No statistical significant associations were found between the haplotypes estimated in the XRCC1 gene and adenoma or carcinoma risk (further data not shown).

Discussion

In this case-control study we investigated the role of polymorphisms, that result in amino acid substitution, of three DNA repair genes involved in NER, BER and HRR.

In this study we did not find an association between the XPD Lys751Gln polymorphism and colorectal carcinoma, but we did find an association between the XPD 751Gln allele and colorectal adenomas, especially with the low-risk adenomas (OR 1.40, 95 % CI 1.03–1.89). Lack of association with the cancer group and the high-risk adenoma group, may be due to small sample size. Another explanation for the observed association in the low-risk adenoma group could be that the polymorphism may play a role in regression of adenomas rather than progression to high-risk adenomas and cancer (advanced neoplasia). Although, it is generally assumed that adenomas grow into cancer or remain in the colon until death, epidemiological data suggests that less than 5 % of adenomas may progress to carcinoma in a lifetime and spontaneous regression of adenomas has been reported [394041]. Hofstad et al. 40 have reported that 60 % of adenomas with diameters less than 10 mm stop growing or go into regression within 3 years of observation. In our material, 63 % of cases with low-risk adenomas were hetero- or homozygous for this polymorphism. However, the characteristics of adenomas going into regression are not known.

Our results indicate that the XPD Lys751Gln polymorphism may predispose slightly to development of colorectal adenomas or that the polymorphism may be of importance for arresting the adenoma-carcinoma sequence in the low-risk phase and facilitate regression of adenomas. Large prospective studies would be required to clarify this issue. XPD polymorphisms have been analyzed particularly in epidemiological studies on skin and smoking-related cancers and no obvious relationship has been found for these types of cancers. Mort et al. 14 and Yeh et al. 15 have reported no significant association between the XPD Lys751Gln polymorphism and colorectal cancer. To our knowledge no studies have been published on the association between XPD polymorphisms and colorectal adenomas.

We found no significant association between the XRCC1 194Trp allele and colorectal adenoma or carcinoma risk. This is not in agreement with the results reported by Abdel-Rahman et al. 12, but consistent with the results reported by Hong et al. 13.

In our study, the XRCC1 399Gln allele was associated with a slightly decreased risk of colorectal adenomas and carcinomas, although statistically significant only for the high-risk adenomas, (OR 0.62, 95% CI 0.41–0.96). This protective role of the XRCC1 399Gln allele is in contrast to previous reports 1213 on this BER gene polymorphism and colorectal cancer risk. Previously, we reported a reduced risk of colorectal adenomas and cancer in association with another BER gene polymorphism, the OGG1 Ser326Cys 42. We have therefore tested the XRCC1 codon 399 and OGG1 codon 326 variant alleles in combination, but it showed no significant association with colorectal adenoma or cancer risk (OR 1.18, 95% CI 0.38–3.68; OR 0.91, 95% CI 0.54–1.52) (further data not shown).

In this study we identified an association between the XRCC1 280His allele and risk of colorectal adenomas and carcinomas, but again, this increased risk was only significant for the adenomas (OR 2.30, 95% CI 1.19–4.46). As far as we know, the KAM study is the first reporting an association between the XRCC1 Arg280His polymorphism and colorectal adenoma and carcinoma risk. There are few reports on this polymorphism. In 1999, Lunn et al. 43 examined the relationship of XRCC1 genotypes and different levels of aflatoxin B1-DNA adducts (51 controls and 69 cases), but no significant effects were observed for the XRCC1 280His allele. Recently, Hong et al. 13 reported an association between the 280His allele and colorectal cancer in combination with the 194Arg allele and the 399Arg allele (OR 1.78, 95 % CI 1.09–2.89). Takanami et al. 44 have reported results suggesting that the XRCC1 Arg280His variant protein has an ineffective or reduced ability to localize a damaged site in the chromosome, thereby reducing the cellular BER/SSB repair efficiency. The variant 280His allele may allow un-repaired SSBs to accumulate, thereby accelerating genomic instability which consequently increases the risk of carcinogenesis. This is supported by our findings of an association between a variant 280His allele and high-risk adenomas. We found that the two polymorphisms XRCC1 Arg280His and XRCC1 Arg399Gln were linked such that the variant allele of XRCC1 codon 280 co-segregated with the wild type allele of XRCC1 codon 399 (p = 0.045). When the XRCC1 Arg280His and XRCC1 Arg399Gln polymorphisms were combined, the effects of the polymorphisms appeared independently of each other. The variant carriers of XRCC1 codon 399 were not statistically significantly, but consistently, at decreased risk of cancer, whereas XRCC1 codon 280 heterozygotes were at increased risk of cancer.

No significant association was found between the XRCC3 Thr241Met polymorphism and colorectal adenomas or carcinomas in our study. This XRCC3 codon 241 polymorphism has previously shown a significant association with colorectal cancer risk 14 (OR 1.52, 95% CI 1.04–2.22) while in another study no association was detected 15. One study reports no association between this XRCC3 polymorphism and colorectal adenoma risk 45. High alcohol consumption has been linked to increased risk of colorectal neoplasia caused by an antifolate effect, resulting in uracil misincorporation into DNA and chromosomal breaks 46.

We have tested the combination of the XRCC3 codon 241 variant allele and alcohol consumption but it showed no significant association with colorectal adenoma or carcinoma risk (OR 1.00, 95% CI 0.98–1.02; OR 0.96, 95% CI 0.92–1.00) (further data not shown). We have also tested the interaction between each of the five DNA repair polymorphisms and cigarette smoking, but they showed no significant association with colorectal adenoma or carcinoma (further data not shown). These results are in agreement with other published studies 4547. To the best of our knowledge, contrary to genetic factors such as metabolic genetic polymorphisms, few studies suggest that the genetic polymorphisms of DNA repair genes may interact with environmental factors such as alcohol drinking and cigarette smoking 39.

The divergence in results from different studies on XRCC1, XRCC3 and XPD polymorphisms may be related to variation in carcinogenic exposure and ethnic origin of the studied populations. Too small sample size and/or the inadequate controlling for certain confounders such as age, gender, alcohol consumption and cigarette smoking may contribute to differing results. It is possible that some of the candidate genes only contribute to colorectal cancer development in combination with certain dietary and /or lifestyle factors. Interaction between various gene products may increase cancer risk. A combination of polymorphisms in these genes may have additive or synergistic effects. For polymorphisms not showing an obvious association with colorectal adenoma or cancer when studied separately, an association with colorectal adenoma or cancer is still possible in combination with other polymorphisms. We have tested the combination of the three polymorphisms in the XRCC1 gene but none of the estimated haplotypes showed a significant association with colorectal adenoma or carcinoma risk.

The design of this study is relatively strong because the controls were recruited from the same cohort as the adenoma and carcinoma cases. The CRC cases and controls have not been matched by age which may affect the results in a study. However, our controls have been screened and found polyp free and the risk of any of them having colon cancer at the time of inclusion is not very likely. The definition of polyp-free controls was based on a negative flexible sigmoidoscopy screening examination. It has been estimated that the risk of erroneously classifying individuals with proximal advanced neoplasia as neoplasia-free is less than 3 % at flexible sigmoidoscopy 4849. Therefore, the risk of misclassification appears small, and it may only contribute to a type II statistical error, reducing the difference between case groups and controls. It cannot be excluded that the present findings are due to chance. The relatively small numbers of the CRC cases, and the low frequency of the variant allele for at least some of the polymorphisms limited our power to detect an assosiation with risk of adenomas and carcinomas.

Conclusion

In conclusion, our results suggest an increased risk for advanced colorectal neoplasia in individuals with XRCC1 Arg280His polymorphism and a reduced risk for persons with XRCC1 Arg399Gln. The increased risk of having low-risk adenomas in contrast to advanced neoplasia for individuals with XPD Lys751Gln polymorphism may suggest a role in regression of adenomas and should be explored in prospective studies of in situ adenomas.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

CFS established the methods in the lab and performed the genotyping analysis of the XRCC1 and XRCC3 genes and prepared the first draft of the paper. She did the data analysis. MS prepared samples for analysis. She also contributed to the manuscript and with advice on data analysis. PCH contributed with statistical advice. SA and IMBL contributed with the pathology of the cancer cases. EJ participated in the collection of blood samples and questionnaires from the cancer cases. ILH participated in collection and quality control of the questionnaires. UBV contributed with genotyping of the XPD gene and together with CFS, MS and EHK interpreted the results. EHK brought the idea of the KAM study and organized it. She was also responsible for the revisions of the manuscript. All authors discussed the results, contributed to interpretation of the results and the final manuscript.

Acknowledgements

This study was supported by the Norwegian Cancer Society (Grant numbers 51024/001 and E01-0851001), Telemark University College (Grant number 22069), the Norwegian Colorectal Cancer Prevention (NORCCAP) study (Grants from the Norwegian Cancer Society and the Department of Health and Social Affairs), with the aid of EXTRA funds from the Norwegian Foundation for Health and Rehabilitation (2001/2/0110), Eastern Norway Regional Health Authority, the Danish Research Agency (Grant numbers 22-02-0356 and 2052-03-0016) and DRAGE, a grant from Danish Ministry of Health, Research Center for Environmental Health's Fund.

We thank Gunter Bock for collecting tumor tissues and Dr. Geir Hoff for critically reviewing the manuscript.

<p>A genetic model for colorectal tumorigenesis</p> Fearon ER Vogelstein B Cell 1990 61 5 759 767 10.1016/0092-8674(90)90186-I 2188735 <p>Lessons from hereditary colorectal cancer</p> Kinzler KW Vogelstein B Cell 1996 87 2 159 170 10.1016/S0092-8674(00)81333-1 8861899 <p>Colorectal cancer: molecules and populations</p> Potter JD J Natl Cancer Inst 1999 91 11 916 932 10.1093/jnci/91.11.916 10359544 <p>Low-penetrance Genes and Their Involvement in Colorectal Cancer Susceptibility</p> De Jong MM Nolte IM Te Meerman GJ Van Der Graaf WT De Vries EG Sijmons RH Hofstra RM Kleibeuker JH Cancer Epidemiol Biomarkers Prev 2002 11 11 1332 1352 12433710 <p>DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk</p> Stern MC Umbach DM Lunn RM Taylor JA Cancer Epidemiol Biomarkers Prev 2002 11 9 939 943 12223443 <p>Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas</p> Ishibe N Sinha R Hein DW Kulldorff M Strickland P Fretland AJ Chow WH Kadlubar FF Lang NP Rothman N Pharmacogenetics 2002 12 2 145 150 10.1097/00008571-200203000-00008 11875368 <p>Polymorphisms in DNA repair and environmental interactions</p> de Boer JG Mutat Res 2002 509 1–2 201 210 12427539 <p>Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans</p> Shen MR Jones IM Mohrenweiser H Cancer Res 1998 58 4 604 608 9485007 <p>Polymorphisms in DNA repair genes and associations with cancer risk</p> Goode EL Ulrich CM Potter JD Cancer Epidemiol Biomarkers Prev 2002 11 12 1513 1530 12496039 <p>No association between base excision repair gene polymorphisms and risk of lung cancer</p> Vogel U Nexo BA Wallin H Overvad K Tjonneland A Raaschou-Nielsen O Biochem Genet 2004 42 11–12 453 460 10.1023/B:BIGI.0000043957.03420.7e 15587988 <p>A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2–3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55</p> Nexo BA Vogel U Olsen A Ketelsen T Bukowy Z Thomsen BL Wallin H Overvad K Tjonneland A Carcinogenesis 2003 24 5 899 904 10.1093/carcin/bgg043 12771034 <p>Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt</p> Abdel-Rahman SZ Soliman AS Bondy ML Omar S El-Badawy SA Khaled HM Seifeldin IA Levin B Cancer Lett 2000 159 1 79 86 10.1016/S0304-3835(00)00537-1 10974409 <p>Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer</p> Hong YC Lee KH Kim WC Choi SK Woo ZH Shin SK Kim H Int J Cancer 2005 <p>Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer</p> Mort R Mo L McEwan C Melton DW Br J Cancer 2003 89 2 333 337 10.1038/sj.bjc.6601061 12865926 <p>Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case-control study in Taiwan</p> Yeh C-C Sung F-C Tang R Chang-Chieh C Hsieh L-L BMC Cancer 2005 5 1 12 549041 15679883 10.1186/1471-2407-5-12 <p>Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk</p> Ratnasinghe D Yao SX Tangrea JA Qiao YL Andersen MR Barrett MJ Giffen CA Erozan Y Tockman MS Taylor PR Cancer Epidemiol Biomarkers Prev 2001 10 2 119 123 11219768 <p>Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy</p> Moullan N Cox DG Angele S Romestaing P Gerard JP Hall J Cancer Epidemiol Biomarkers Prev 2003 12 11 Pt 1 1168 1174 14652276 <p>Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation</p> Griffin CS Simpson PJ Wilson CR Thacker J Nat Cell Biol 2000 2 10 757 761 10.1038/35036399 11025669 <p>The XRCC2 and XRCC3 repair genes are required for chromosome stability in mammalian cells</p> Cui X Brenneman M Meyne J Oshimura M Goodwin EH Chen DJ Mutat Res 1999 434 2 75 88 10422536 <p>XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects</p> Matullo G Palli D Peluso M Guarrera S Carturan S Celentano E Krogh V Munnia A Tumino R Polidoro S Piazza A Vineis P Carcinogenesis 2001 22 9 1437 1445 10.1093/carcin/22.9.1437 11532866 <p>Variants in DNA double-strand break repair genes and breast cancer susceptibility</p> Kuschel B Auranen A McBride S Novik KL Antoniou A Lipscombe JM Day NE Easton DF Ponder BA Pharoah PD Dunning A Hum Mol Genet 2002 11 12 1399 1407 10.1093/hmg/11.12.1399 12023982 <p>XRCC3 polymorphisms and risk of lung cancer</p> Jacobsen NR Raaschou-Nielsen O Nexo B Wallin H Overvad K Tjonneland A Vogel U Cancer Lett 2004 213 1 67 72 10.1016/j.canlet.2004.04.033 15312685 <p>A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer</p> Winsey SL Haldar NA Marsh HP Bunce M Marshall SE Harris AL Wojnarowska F Welsh KI Cancer Res 2000 60 20 5612 5616 11059748 <p>No association between the DNA repair gene XRCC3 T241M polymorphism and risk of skin cancer and breast cancer</p> Jacobsen NR Nexo BA Olsen A Overvad K Wallin H Tjonneland A Vogel U Cancer Epidemiol Biomarkers Prev 2003 12 6 584 585 12815008 <p>DNA excision repair pathways</p> Lindahl T Karran P Wood RD Curr Opin Genet Dev 1997 7 2 158 169 10.1016/S0959-437X(97)80124-4 9115419 <p>Repair of DNA lesions: mechanisms and relative repair efficiencies</p> Braithwaite E Wu X Wang Z Mutat Res 1999 424 1–2 207 219 10064862 <p>Correction of xeroderma pigmentosum complementation group D mutant cell phenotypes by chromosome and gene transfer: involvement of the human ERCC2 DNA repair gene</p> Flejter WL McDaniel LD Johns D Friedberg EC Schultz RA Proc Natl Acad Sci U S A 1992 89 1 261 265 48216 1729695 <p>Molecular mechanism of nucleotide excision repair</p> de Laat WL Jaspers NG Hoeijmakers JH Genes Dev 1999 13 7 768 785 10197977 <p>Human xeroderma pigmentosum group D gene encodes a DNA helicase</p> Sung P Bailly V Weber C Thompson LH Prakash L Prakash S Nature 1993 365 6449 852 855 10.1038/365852a0 8413672 <p>Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH</p> Coin F Bergmann E Tremeau-Bravard A Egly JM Embo J 1999 18 5 1357 1366 1171225 10064601 10.1093/emboj/18.5.1357 <p>ERCC2/XPD gene polymorphisms and cancer risk</p> Benhamou S Sarasin A Mutagenesis 2002 17 6 463 469 10.1093/mutage/17.6.463 12435843 <p>ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review</p> Benhamou S Sarasin A Am J Epidemiol 2005 161 1 1 14 10.1093/aje/kwi018 15615908 <p>The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50–64 years</p> Gondal G Grotmol T Hofstad B Bretthauer M Eide TJ Hoff G Scand J Gastroenterol 2003 38 6 635 642 10.1080/00365520310003002 12825872 <p>ClinicalTrials.gov</p> http://www.clinicaltrials.gov <p>A simple salting out procedure for extracting DNA from human nucleated cells</p> Miller SA Dykes DD Polesky HF Nucleic Acids Res 1988 16 3 1215 334765 3344216 <p>Two regions in chromosome 19q13.2–3 are associated with risk of lung cancer</p> Vogel U Laros I Jacobsen NR Thomsen BL Bak H Olsen A Bukowy Z Wallin H Overvad K Tjonneland A Nexo BA Raaschou-Nielsen O Mutat Res 2004 546 1–2 65 74 14757194 <p>Hplus</p> http://qge.fhcrc.org/hplus <p>A method for the assessment of disease associations with single-nucleotide polymorphism haplotypes and environmental variables in case-control studies</p> Zhao LP Li SS Khalid N Am J Hum Genet 2003 72 5 1231 1250 1180275 12704570 10.1086/375140 <p>Epidemiology of polyps in the rectum and colon. Recovery and evaluation of unresected polyps 2 years after detection</p> Hoff G Foerster A Vatn MH Sauar J Larsen S Scand J Gastroenterol 1986 21 7 853 862 3775252 <p>Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years</p> Hofstad B Vatn MH Andersen SN Huitfeldt HS Rognum T Larsen S Osnes M Gut 1996 39 3 449 456 8949653 <p>National Polyp Study data: evidence for regression of adenomas</p> Loeve F Boer R Zauber AG Van Ballegooijen M Van Oortmarssen GJ Winawer SJ Habbema JD Int J Cancer 2004 111 4 633 639 10.1002/ijc.20277 15239144 <p>GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer</p> Hansen R Saebo M Skjelbred CF Nexo BA Hagen PC Bock G Bowitz Lothe IM Johnson E Aase S Hansteen IL Vogel U Kure EH Cancer Lett 2005 15946795 <p>XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency</p> Lunn RM Langlois RG Hsieh LL Thompson CL Bell DA Cancer Res 1999 59 11 2557 2561 10363972 <p>The Arg280His polymorphism in X-ray repair cross-complementing gene 1 impairs DNA repair ability</p> Takanami T Nakamura J Kubota Y Horiuchi S Mutat Res 2005 582 1–2 135 145 15781218 <p>XRCC2 and XRCC3 polymorphisms are not associated with risk of colorectal adenoma</p> Tranah GJ Giovannucci E Ma J Fuchs C Hankinson SE Hunter DJ Cancer Epidemiol Biomarkers Prev 2004 13 6 1090 1091 15184273 <p>Folate, methionine, and alcohol intake and risk of colorectal adenoma</p> Giovannucci E Stampfer MJ Colditz GA Rimm EB Trichopoulos D Rosner BA Speizer FE Willett WC J Natl Cancer Inst 1993 85 11 875 884 8492316 <p>The association of the DNA repair gene XRCC3 Thr241Met polymorphism with susceptibility to colorectal cancer in a Chinese population</p> Jin MJ Chen K Song L Fan CH Chen Q Zhu YM Ma XY Yao KY Cancer Genet Cytogenet 2005 163 1 38 43 10.1016/j.cancergencyto.2005.05.001 16271954 <p>Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380</p> Lieberman DA Weiss DG Bond JH Ahnen DJ Garewal H Chejfec G N Engl J Med 2000 343 3 162 168 10.1056/NEJM200007203430301 10900274 <p>Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings</p> Imperiale TF Wagner DR Lin CY Larkin GN Rogge JD Ransohoff DF N Engl J Med 2000 343 3 169 174 10.1056/NEJM200007203430302 10900275

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/6/67/prepub